Travis T. Sims, M.D., M.P.H., F.A.C.O.G
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Dr. Travis T. Sims
Dr. Sims is assistant professor in the Department of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. As a gynecologic oncologist he is committed to providing exemplary evidence-based patient care, advancing his specialty through research/clinical investigation and educating the next generation of surgeons/oncologists. Dr. Sims earned a Bachelor of Science in Neuroscience from the University of Michigan, a Doctor of Medicine from Northwestern University Feinberg School of Medicine and a Master of Public Health in Healthcare Management from The University of Texas Health Science Center at Houston School of Public Health. He Dr. Sims completed a residency in Obstetrics and Gynecology at The University of Texas Southwestern Medical Center/Parkland Memorial Hospital followed by a fellowship in Gynecologic Oncology at MD Anderson Cancer Center. His time as a fellow strengthened his skills as a clinician, surgeon, researcher, and educator.
His research interest expands upon his experience in translational research and clinical trial design with the goal of continuing to identify pertinent clinical problems and design trials that provide evidence-based solutions. Dr. Sims has a special research interest focused on characterizing the gut and tumor microbiome to elucidate its influence on carcinogenesis, prognosis and outcomes in gynecological cancer. He has authored and co-authored numerous articles in high-impact peer-reviewed journals on these and other subjects.
Dr. Sims is an active member of the American Society of Clinical Oncology and Society of Gynecologic Oncologists. In addition, he serves as reviewer for several journals including Gynecologic Oncology, and the International Journal of Gynecological Cancer.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Experience & Service
Other Professional Positions
Board Member, Texas Society of clinical Oncology (TxSCO), 2024 - Present
Break Through Cancer, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, ASCO, Houston, 2021
Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Member, The Society of Gynecologic Oncology (SGO) Diversity & Inclusion Committee, Houston, TX, 2020 - Present
President, Graduate Medical Education (GME) House Staff Senate - The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Vice President, Graduate Medical Education (GME) House Staff Senate- The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019
Member, NW FSOM Curriculum Review Panel Northwestern University Feinberg School of Medicine, Chicago, IL, 2011 - 2012
Vice President, Student National Medical Association (SNMA) - Northwestern University Feinberg School of Medicine, Chicago, IL, 2010 - 2014
Extramural Institutional Committee Activities
Member, NRG Oncology, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, NRG Oncology, National Clinical Trials Network, 2026 - Present
Reviewer, IRB Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, MD Anderson Medical Staff Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Fellowship Admissions Subcommittee - The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Handoff Communication I-Pass Taskforce - The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Student & Trainee Leadership Committee - The University of Texas M Anderson Cancer Center - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2019 - Present
Honors & Awards
| 2024 | NIH National Cancer Institute - Paul Calabresi Career Developmen Award for Clinical Oncology K12 Scholar, NIH National Cancer Institute - Paul Calabresi Career Development Award for Clinical Oncology |
| 2024 | SGO Outstanding Leadership Award |
| 2023 | NIH K12 MD Anderson Paul Calabresi Scholar |
| 2022 | Clinical Resident/Fellow Excellence Award for Teaching, The University of Texas MD Anderson Cancer Center |
| 2022 | Robert A. Winn Diversity in Clinical Trials Career Development Program Award |
| 2022 | MD Anderson Leading Clinical Research Faculty Learning Series |
| 2022 | Clinical Resident/Fellow Excellence Award for Teaching, The University of Texas MD Anderson Cancer Center |
| 2021 | Conquer Cancer American Society of Clinic Oncology (ASCO) Merit Award |
| 2020 - 2021 | Conquer Cancer American Society of Clinic Oncology (ASCO) Merit Award, ASCO |
| 2020 | Conquer Cancer American Society of Clinic Oncology (ASCO) Merit Award |
| 2019 | MD Anderson First Annual PRIME TR Retreat (Program for Innovative Microbiome and Translational Research), UT MD Anderson Cancer Center, Houston, Texas |
| 2019 | Dr. Chien-Tien Hsu Fellow Scholarship in Gynecologic Oncology, Hsu Medical Education Foundation |
| 2019 | Felix Rutledge Society Meeting Poster Travel Award, UT MD Anderson Cancer Center, Houston, Texas |
| 2018 | Excellence in Gynecologic Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas |
| 2011 | Bluhm Cardiovascular Institute Summer Student Award, Northwestern University Feinberg School of Medicine |
| 2011 | Student LIFE Ambassador, Northwestern University Feinberg School of Medicine |
| 2010 | Medical School Student Scholar Scholarship, Northwestern University Feinberg School of Medicine |
| 2009 | Charles Ross Research Summer Fellowship Award, University of Michigan Medical School |
| 2008 | Undergraduate Research Opportunity Program Biomedical Summer Fellowship Award, University of Michigan |
| 2006 | Health Science Scholars Program, University of Michigan |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Calabresi Scholar & Physician-Scientist “Identification and treatment of minimal residual disease after frontline therapy in advance stage ovarian cancer”. Conference. Spring 2025 Calabresi Scholar and Physician-Scientist Symposium, Houston Texas. Houston, Texas, US.
- 2023. Foundations of Endometrial Cancer. Conference. Foundations of Endometrial Cancer. Houston, TX, US.
- 2023. Clinical Trial Portfolio Review: Endometrial Cancer. Conference. Clinical Trial Portfolio Review: Endometrial Cancer. Houston, TX, US.
- 2019. Compositional and Temporal Changes of the Gut Microbiome in Women with Cervical Cancer Undergoing Chemoradiation: Does it Predict Response? Poster Presentation. Conference. Compositional and Temporal Changes of the Gut Microbiome in Women with Cervical Cancer Undergoing Chemoradiation: Does it Predict Response? Poster Presentation. Houston, TX, US.
- 2019. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Age and BMI Matched Healthy Controls. Poster Presentation. Conference. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Age and BMI Matched Healthy Controls. Poster Presentation. Houston, TX, US.
Regional Presentations
- 2025. MRD Advance Stage Ovarian Cancer. Conference. McAllen, Texas, US.
- 2024. Texas Society of Clinical Oncology: HER2-targeted therapy UPDATES in Gynecologic Cancers. Conference. Texas Society of Clinical Oncology (TxSCO) Annual Conference. San Antonio, Texas, US.
- 2024. Minimal Residual Disease in Ovarian Cancer: Pronostoc Value, Biological Underpinnings, and Therapeutic Opportunities. Conference. Minimal Residual Disease in Ovarian Cancer: Pronostoc Value, Biological Underpinnings, and Therapeutic Opportunities. Houston, US.
- 2017. Closed incision negative pressure therapy should be considered for obese patients undergoing laparotomy for gynecologic malignancies. Poster Presentation. Conference. Closed incision negative pressure therapy should be considered for obese patients undergoing laparotomy for gynecologic malignancies. Poster Presentation. Austin, TX, US.
- 2011. Quantitative Approach to Mitral Valve Repair: Linking Anatomy and the Pathophysiology of Mitral Regurgitation. Poster Presentation. Conference. Quantitative Approach to Mitral Valve Repair: Linking Anatomy and the Pathophysiology of Mitral Regurgitation. Poster Presentation. Chicago, IL, US.
- 2011. Quantitative Approach to Mitral Valve Repair: Linking Anatomy and the Pathophysiology of Mitral Regurgitation (Oral Presentation). Conference. Quantitative Approach to Mitral Valve Repair: Linking Anatomy and the Pathophysiology of Mitral Regurgitation (Oral Presentation). Chicago, IL, US.
National Presentations
- 2026. Phase II study of cadonilimab monotherapy for recurrent small cell neuroendocrine carcinoma of the cervix. Poster. Society of Gynecologic Oncology, US.
- 2025. Clinic Trail Design. Conference. Break Through Cancer (BTC). Baltimore, Maryland, US.
- 2021. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer. Oral Presentation. Conference. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer. Oral Presentation, US.
- 2021. An analysis of tumor microbial diversity and composition between women with cervical cancer in Botswana and the United States. Poster Presentation. Conference. An analysis of tumor microbial diversity and composition between women with cervical cancer in Botswana and the United States. Poster Presentation, US.
- 2021. “The Role of the Cervicovaginal and Gut Microbiome in HPV Gynecologic Malignancies”. Conference. “The Role of the Cervicovaginal and Gut Microbiome in HPV Gynecologic Malignancies”, US.
- 2019. Exceptional Response to Radiation Therapy for Cervical Cancers is Associated with Higher Predicted Tumor Neoantigen Burden and Selective Loss of Neoantigens. Oral Presentation. Conference. Exceptional Response to Radiation Therapy for Cervical Cancers is Associated with Higher Predicted Tumor Neoantigen Burden and Selective Loss of Neoantigens. Oral Presentation. Chicago, IL, US.
- 2019. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Healthy Controls. Oral Presentation. Conference. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Healthy Controls. Oral Presentation. Miami, FL, US.
- 2019. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Age and BMI Matched Healthy Controls. Poster Presentation. Conference. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Age and BMI Matched Healthy Controls. Poster Presentation. Honolulu, HI, US.
- 2017. Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies. Poster Presentation. Conference. Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies. Poster Presentation. San Diego, CA, US.
- 2017. Risk-Reducing Salpingo-Oophorectomy for BRCA carriers: is there a benefit to combined breast surgery? Poster Presentation. Conference. Risk-Reducing Salpingo-Oophorectomy for BRCA carriers: is there a benefit to combined breast surgery? Poster Presentation. San Diego, CA, US.
- 2017. Combining Whole Pelvic Radiation with Chemotherapy in Stage IVB Cervical Cancer: A Novel Treatment Strategy. Oral Presentation. Conference. Combining Whole Pelvic Radiation with Chemotherapy in Stage IVB Cervical Cancer: A Novel Treatment Strategy. Oral Presentation. National Harbor, MD, US.
- 2016. The Potential Role of Pelvic Radiation in Stage IVB Cervical Carcinoma. Poster Presentation. Conference. The Potential Role of Pelvic Radiation in Stage IVB Cervical Carcinoma. Poster Presentation. Sedna, AZ, US.
- 2015. Emphasis on Systemic Therapy for Women with Pelvic Bone involvement at Time of Diagnosis of Cervical Cancer. Poster Presentation. Conference. Emphasis on Systemic Therapy for Women with Pelvic Bone involvement at Time of Diagnosis of Cervical Cancer. Poster Presentation. Santa Rosa, CA, US.
- 2014. Distant Failure After Treatment of Para-Aortic Lymph Node Metastases. Poster Presentation. Conference. Distant Failure After Treatment of Para-Aortic Lymph Node Metastases. Poster Presentation. Truckee, CA, US.
- 2014. Testing for Familial BRCA1-2 Mutations: Implications for Genetic Counseling and Risk Assessment. Poster Presentation. Conference. Testing for Familial BRCA1-2 Mutations: Implications for Genetic Counseling and Risk Assessment. Poster Presentation. Chicago, IL, US.
International Presentations
- 2024. Clinician Needs for Bioelectronics. Conference. Clinician Needs for Bioelectronics. Paris, GB.
- 2021. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline and maintenance therapy. Oral Featured Poster. Conference. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline and maintenance therapy. Oral Featured Poster, US.
- 2021. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. Poster Presentation. Conference. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. Poster Presentation. Chicago, US.
- 2020. Gut microbiome diversity as an independent predictor of survival in cervical cancer patients receiving chemoradiation. Poster Presentation. Conference. Gut microbiome diversity as an independent predictor of survival in cervical cancer patients receiving chemoradiation. Poster Presentation. Chicago, US.
- 2020. Compositional and Temporal Changes of the Gut Microbiome in Women with Cervical Cancer Undergoing Chemoradiation: Does it Predict Response? Feature Poster Presentation. Conference. Compositional and Temporal Changes of the Gut Microbiome in Women with Cervical Cancer Undergoing Chemoradiation: Does it Predict Response? Feature Poster Presentation. Totonto, CA.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | NIH National Cancer Institute K12 Paul Calabresi Career Development Award |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Winn Career Development Award |
| Funding Source: | Bristol Myers Squibb Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Eyada, M, Michael, V, Patel, S, How, JA, Wilke, RN, Jazaeri, AA, Fleming, N, Soliman, PT, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide combined with bevacizumab in recurrent heavily pre-treated ovarian cancer. International Journal of Gynecological Cancer 36(8), 2026. e-Pub 2026. PMID: 42259216.
- Sims, TT, Sood, AK, Westin, SN, Rangel, KM, Fleming, N. Correlation of BRCA and homologous recombination deficiency status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline therapy. International Journal of Gynecological Cancer 36(7), 2026. e-Pub 2026. PMID: 41680019.
- Celestino, N, Asare, A, Malpica, A, Rampisela, D, Dockery, JL, Patel, S, Soliman, PT, Sims, TT. Mixed tumor of the vagina with atypical features. Gynecologic Oncology Reports 65, 2026. e-Pub 2026. PMID: 42199933.
- Kouzy, R, Rooney, M, Cha, E, Vinjamuri, S, Wu, H, Kouzi, ZE, Mohamad, O, Sims, TT, Weil, CR, Taku, N, Lin, LL, Jhingran, A, Eifel, PJ, Joyner, MM, Colbert, LE, Klopp, AH. AI based sentiment analysis of online discussions related to cervical brachytherapy. Technical Innovations and Patient Support in Radiation Oncology 36, 2025. e-Pub 2025. PMID: 41473390.
- Clark HD, Aghlara-Fotovat S, Schladenhauffen J, Debonis J, Amador-Molina JC, Nash A, Jain M, Newman R, Jansen L, Andreas K, Rangel K, Sims TT, Fellman B, Ullman CD, Yeku O, Bregar AJ, Blakely AM, Mathews C, Igoshin OA, Haymaker C, Oberholzer J, Rios P, Lopez D, Nasir H, Joshi I, Chakrabarti R, Veiseh O, Jazaeri AA, Westin SN. First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma. medRxiv, 2025. e-Pub 2025. PMID: 41292632.
- Rajan, SS, Ning, M, Jacobson, M, Simiele, SJ, Bruno, TL, Kouzy, R, Court, K, Cisneros-Napravnik, T, Yu, H, Stafford, J, Kim, Y, Mathew, GG, Cordova, RA, Domingo, M, Jhingran, A, Lin, LL, Joyner, MM, Sims, TT, Colbert, LE, Venkatesan, AM, Klopp, AH. Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy. Brachytherapy 24(6):844-853, 2025. e-Pub 2025. PMID: 40816920.
- Sims, TT, Court, K, El Alam, MB, Ramatlho, P, Ketlametswe, R, Ning, M, Robertson, ES, Schmeler, KM, Colbert, LE, Klopp, AH, Grover, S. Cervical and Tumor-Associated Microbiomes in Botswana Women With and Without HIV With Carcinoma of the Cervix Before and After Definitive Chemoradiation. JCO Global Oncology 11, 2025. e-Pub 2025. PMID: 41160784.
- Knisely, A, Dai, Y, Barlow, GL, Lee, S, Lawson, BC, Clark, HD, Fellman, B, Yuan, Y, Lu, W, Lubo Julio, IC, Lazcano, RN, Chelvanambi, M, Melendez, B, Singh, BB, Singh, B, Wani, K, Chen, J, Yeh, CC, Gao, J, Barnes, S, Shi, O, Khan, KB, Serrano, A, Gomez Bolanos, L, Scalise, CB, Cheung, SK, Dutta, P, Velichko, S, ElNaggar, AC, Liu, MC, Wilke, RN, How, JA, Ramondetta, LM, Boruta II, DM, Richardson, G, Shafer, A, Westin, SN, Sims, TT, Sood, AK, Ramirez, PT, Lazar, A, Soliman, PT, Lu, KH, Haymaker, CL, Solis Soto, LM, Wargo, J, Grisham, RN, Wucherpfennig, K, Wang, L, Jazaeri, AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy. Clinical Cancer Research 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
- Kim, M, Asare, A, Dockery, JL, Hameed, N, Sims, TT. Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma. Gynecologic Oncology Reports 60, 2025. e-Pub 2025. PMID: 40687920.
- Son, J, Cain, K, Marten, CA, Dwyer, KW, Sims, TT, Taylor, JS. Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer. Gynecologic Oncology Reports 56, 2024. e-Pub 2024. PMID: 39431057.
- Wilke RN, Liu J, Westin SN, Sims TT, Fellman BM, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. International Journal of Gynecological Cancer 35(11), 2024. e-Pub 2024. PMID: 39414313.
- Manzar GS, Alam MBE, Lynn EJ, Karpinets TV, Harris T, Lo D, Yoshida-Court K, Napravnik TC, Sammouri J, Lin D, Andring LM, Bronk J, Wu X, Sims TT, Mathew G, Schmeler KM, Eifel PJ, Jhingran A, Lin LL, Joyner MM, Zhang J, Futreal A, Klopp AH, Colbert LE. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. Brachytherapy 23(2):123-135, 2024. e-Pub 2023. PMID: 38129211.
- Eyada, M, Michael, V, Fellman, B, Patel, S, Soliman, PT, How, JA, Jazaeri, AA, Fleming, N, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Eyada, M, Fellman, B, Patel, S, Michael, V, Soliman, PT, Sims, TT, How, JA, Jazaeri, AA, Fleming, N, Ramondetta, LM, Westin, SN. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Colbert LE, El Alam MB, Wang R, Karpinets T, Lo D, Lynn EJ, Harris TA, Elnaggar JH, Yoshida-Court K, Tomasic K, Bronk JK, Sammouri J, Yanamandra AV, Olvera AV, Carlin LG, Sims T, Delgado Medrano AY, Napravnik TC, O'Hara M, Lin D, Abana CO, Li HX, Eifel PJ, Jhingran A, Joyner M, Lin L, Ramondetta LM, Futreal AM, Schmeler KM, Mathew G, Dorta-Estremera S, Zhang J, Wu X, Ajami NJ, Wong M, Taniguchi C, Petrosino JF, Sastry KJ, Okhuysen PC, Martinez SA, Tan L, Mahmud I, Lorenzi PL, Wargo JA, Sims, TT, Klopp AH. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell 41(11):1945-1962.e11, 2023. e-Pub 2023. PMID: 37863066.
- Foster KI, Handley KF, Glassman D, Sims TT, Javadi S, Palmquist SM, Saleh MM, Fellman BM, Fleming ND, Bhosale PR, Sood AK. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. Int J Gynecol Cancer 33(6):937-943, 2023. e-Pub 2023. PMID: 36948527.
- Yoshida-Court K, Karpinets TV, Mitra A, Solley TN, Dorta-Estremera S, Sims TT, Delgado Medrano AY, El Alam MB, Ahmed-Kaddar M, Lynn EJ, Sastry KJ, Zhang J, Futreal A, Nick A, Lu K, Colbert LE, Klopp AH. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. PLoS One 18(1):e0279590, 2023. e-Pub 2023. PMID: 36607962.
- Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
- Karpinets TV, Wu X, Solley T, El Alam MB, Sims TT, Yoshida-Court K, Lynn E, Ahmed-Kaddar M, Biegert G, Yue J, Song X, Sun H, Petrosino JF, Mezzari MP, Okhuysen P, Eifel PJ, Jhingran A, Lin LL, Schmeler KM, Ramondetta L, Ajami N, Jenq RR, Futreal A, Zhang J, Klopp AH, Colbert LE. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer 22(1):945, 2022. e-Pub 2022. PMID: 36050658.
- Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res 10(2):259-271, 2022. e-Pub 2022. PMID: 35045973.
- Sims TT Jazaeri AA. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. Int J Gynecol Cancer 31(11):1408-1409, 2021. e-Pub 2021. PMID: 34551893.
- Biegert G, El Alam MB, Karpinets T, Wu X, Sims TT, Yoshida-Court K, Lynn EJ, Yue J, Medrano AD, Petrosino J, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Klopp AH, Colbert LE. Diversity and composition of gut microbiome of cervical cancer patients: Do results of 16S rRNA sequencing and whole genome sequencing approaches align?. J Microbiol Methods 185:106213, 2021. e-Pub 2021. PMID: 33785357.
- Sims TT, Boruta DM. Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?. Gynecol Oncol 161(2):331-332, 2021. e-Pub 2021. PMID: 33902864.
- Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol 4(1):237, 2021. e-Pub 2021. PMID: 33619320.
- El Alam MB, Sims TT, Kouzy R, Biegert GWG, JABI J, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One 16(3):e0247905, 2021. e-Pub 2021. PMID: 33662003.
- Sims TT, Biegert GWG, Ramogola-Masire D, Ngoni K, Solley T, Ning MS, El Alam MB, Mezzari M, Petrosino J, Zetola NM, Schmeler KM, Colbert LE, Klopp AH, Grover S. Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer. Int J Gynecol Cancer 30(8):1151-1156, 2020. e-Pub 2020. PMID: 32675252.
- Mitra A, Grossman Biegert GW, Delgado AY, Karpinets TV, Solley TN, Mezzari MP, Yoshida-Court K, Petrosino JF, Mikkelson MD, Lin L, Eifel P, Zhang J, Ramondetta LM, Jhingran A, Sims TT, Schmeler K, Okhuysen P, Colbert LE, Klopp AH. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys 107(1):163-171, 2020. e-Pub 2020. PMID: 31987960.
- Perkins V, Moore K, Vesely S, Matsuo K, Mostofizadeh S, Sims TT, Lea J, Barnes D, Chen S, Carlson M, Roman L, Monk BJ, Holman LL. Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol 156(1):100-106, 2020. e-Pub 2020. PMID: 31810653.
- Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol 155(2):237-244, 2019. e-Pub 2019. PMID: 31500892.
- Manders DB, Sims TT, Bailey A, Hwang L, Richardson DL, Miller DS, Kehoe SM, Albuquerque KV, Lea JS. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol 41(12):1225-1230, 2018. e-Pub 2018. PMID: 29782361.
- Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. Am J Clin Oncol 41(11):1137-1141, 2018. e-Pub 2018. PMID: 29521650.
Review Articles
- Lainé A, Sims TT, Le Saux O, Ray-Coquard I, Coleman RL. Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. Curr Oncol Rep 23(12):148, 2021. e-Pub 2021. PMID: 34751835.
- Sims TT, Colbert LE, Klopp AH. The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer. J Immunother Precis Oncol 4(2):72-78, 2021. e-Pub 2021. PMID: 35663536.
- Sims TT, Klopp AH. Intensified Systemic Therapy Regimens in Combination With Definitive Radiation for Treatment of Cervical Cancer. Semin Radiat Oncol 30(4):265-272, 2020. e-Pub 2020. PMID: 32828382.
Other Articles
- Court, K, Karpinets, T, Mitra, A, Solley, T, Dorta-Estremera, S, Sims, TT, Delgado Medrano, AY, Alam, MB, Ahmed-Kaddar, M, Lynn, EJ, Jagannatha Sastry, K, Zhang, J, Futreal, A, Nick, AM, Lu, K, Colbert, LE, Klopp, AH Erratum. PloS one 19(11):e0314643, 2024. PMID: 39576772.
- Sims TT, Colbert LE, Karpinets T, Grossman Biegert GW, Delgado AY, Mezzari MP, Solley T, Mitra A, Lin LL, Ramondetta LM, Jazaeri AA, Frumovitz M, Jhingran A, Schmeler K, Wargo J, Klopp AH Compositional and temporal changes of the gut microbiome in women with cervical cancer undergoing chemoradiation: Does it predict response?. Gynecol Oncol 159:35-36, 2021.
Abstracts
- Sims TT, Sood AK, Westin SN, Rangel K, Fleming ND. Correlation of BRCA and homologous recombination deficiency status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline therapy. Society of Gynecologic Oncology, 2026. e-Pub 2026. PMID: 41680019.
- Sims TT, Glassman D, Handley K, Asare A, Foster K, Sims T, Fleming N, Celestino J, Lee S, Sood A. Does cancer appearance reflect genetic status? The relationship between the gross appearance of high-grade serous ovarian cancer and BRCA mutation status 190:S227-S228, 2024. e-Pub 2024.
- Sims T, Alam ME, Ning M, Schmeler K, Ramondetta L, Colbert L, Klopp A. The cervical and tumor-associated microbiome among Botswanan women with HIV diagnosed with high-grade cervical dysplasia and squamous cell carcinoma of the cervix. Gynecol Oncol 190:S234-S235, 2024. e-Pub 2024.
- Nitecki R, Liu J, Westin S, Fellman B, Sims T, Pham M, Rangel K, Sey E, Rauh-Hain J, Lu K, Sood A, Fleming N. Maximizing effectiveness: Chemotherapy response score and homologous recombination deficiency strategies. Gynecol Oncol 190:S397-S398, 2024. e-Pub 2024.
- Knisely A, Lee S, Sims TT, Nitecki R, How J, Fellman B, Scalise CB, Dutta P, ElNaggar A, Liu M, Taylor J, Ramondetta L, Grinsfelder M, Cobb L, Boruta D, Richardson G, Soliman P, Shafer A, Westin S, Fleming N, Sims T, Sood A, Ramirez P, Lu K, Jazaeri A. Prognostic implications of minimal residual disease detection by second-look laparoscopy and circulating tumor DNA among patients with ovarian cancer after front-line therapy. gyn oncol 190:S19-S20, 2024. e-Pub 2024.
- Knisely A, Dai Y, Lee S, Wilke RN, How J, Fellman B, Taylor J, Ramondetta L, Grinsfelder M, Cobb L, Boruta D, Richardson G, Soliman P, Shafer A, Westin S, Fleming N, Sims T, Sood A, Ramirez P, Lu K, Jazaeri A. EV273/# 1097 Minimal residual disease as a prognostic marker and opportunity for intervention in advanced ovarian cancer. ScienceDirect 34:A226, 2024. e-Pub 2024.
- Eyada M, Michael V, Fellman BM, Patel S, Soliman PT, How JA, Jazaeri AA, Fleming ND, Sood AK, Westin SN, Sims TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. ASCO 42(16):5517-5517, 2024. e-Pub 2024.
- Eyada M, Fellman BM, Patel S, Michael V, Soliman PT, Sims TT, How JA, Jazaeri AA, Fleming ND, Ramondetta LM, Westin SN. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. ASCO 42(16):5548-5548, 2024. e-Pub 2024.
- Knisely A, Nitecki R, Rauh-Hain J, Hillman R, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims TT, Sood AK, Ramirez PT, Lu KH, Jazaeri AA. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer. AACR Meet Abstr Online 84:A077-A077, 2024. e-Pub 2024.
- Knisely A, Nitecki R, Rauh-Hain J, Hillman R, Taylor JS, Ramondetta LM, Grinsfelder MO, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims TT, Sood AK, Ramirez PT, Lu KH, Jazaeri AA. The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer. AMER ASSOC Cancer Research 84(5), 2024. e-Pub 2024.
- Manzar GS, El Alam MB, Lynn EJ, Karpinets TV, Harris T, Lo D, Yoshida-Court K, Napravnik TC, Sammouri J, Lin D, Andring LM, Bronk J, Wu X, Sims TT, Mathew G, Schmeler KM, Eifel PJ, Jhingran A, Lin LL, Joyner MM, Zhang J, Futreal A, Klopp AH, Colbert LE. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. ScienceDirect 23(2):123-135, 2024. e-Pub 2024.
- Florentia D, Ashish V D, Priyadharsini N, Neus B, Randy C, Pranoti S, Yasmine H, Devarati M, Roi W, Su SY, Hanna E, Esmaeli B, Sims TT, Pettaway CA, Amaria RN, Glitza IC, Losh J, Ajami NJ, Woodman S, Wargo JA, Futreal P, McQuade J. 1256 Delineating the role of the microbiome and tumor micro environment interactions driving mucosal melanoma response and resistance to immune checkpoint inhibitor treatment. BMJ 12(2), 2024.
- Knisely A, Nitecki R, Dang M, Lee S, Fellman B, Rauh-Hain J, Hillman R, Taylor J, Ramondetta L, Grinsfelder M, Cobb L, Boruta D, Richardson G, Soliman P, Shafer A, Westin S, Fleming N, Sims T, Sood A, Ramirez P, Lu K, Wang L, Jazaeri A. Transforming frontline therapy in ovarian cancer by focusing on surgically documented minimal residual disease after frontline treatment (1178). Gynecol Oncol 176(1):S122-S123, 2023. e-Pub 2023.
- Knisely A, Sims T, Griffin D, Ramondetta L, Collins S, Cobb L, Boruta D, Richardson G, Sood A, Ramirez P, Lu K, Jazaeri A. RF2 Feasibility and preliminary results of the first clinical trial targeting minimal residual disease in patients with homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol 173:S5, 2023. e-Pub 2023.
- How J, Westin SN, Sims TT, Lito K, Celestino J, Rangel KM, Peng W, Wang L, Jazaeri AA. Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer. ASCO 41(16):TPS5619-TPS5619, 2023. e-Pub 2023.
- Foster KI, Handley KF, Glassman D, Sims TT, Javadi S, Palmquist SM, Saleh MM, Fellman BM, Fleming ND, Bhosale PR, Sood AK. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: A retrospective cohort study. SciencDirect 33(6):937-943, 2023. e-Pub 2023.
- Westin SN, Yeku OO, Sims TT, Bregar A, Andreas K, Soliman E, Jain M, Ullmann CD, Jazaeri AA. A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. ASCO 41(16):TPS5616-TPS5616, 2023. e-Pub 2023.
- Knisely A, Wilke RN, Fellman BM, Rauh-Hain JA, Hillman RT, Taylor JS, Ramondetta LM, Onstad M, Cobb LP, Boruta DM, Richardson G, Soliman PT, Shafer A, Westin SN, Fleming ND, Sims TT, Sood AK, Ramirez PT, Lu KH, Jazaeri AA. Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer. ACSO 41(16):5549-5549, 2023. e-Pub 2023.
- Westin SN, Sims T, Andreas K, Soliman E, Jain M, Dansky Ullmann CA, Jazaeri AA. Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. AACR Meet Abstr Online 83(8):CT122-CT122, 2023. e-Pub 2023.
- Yoshida-Court K, Karpinets TV, Mitra A, Solley TN, Dorta-Estremera S, Sims TT, Delgado Medrano AY, El Alam MB, Ahmed-Kaddar M, Lynn EJ, Sastry K, Zhang J, Futreal A, Nick A, Lu K, Colbert LE, Klopp AH. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. PLoS One 18(1):e0279590, 2023. e-Pub 2023.
- Karpinets TV, Wu X, Solley T, El Alam MB, Sims TT, Lynn E, Ahmed-Kaddar M, Biegert G, Yue J, Song X, Sun H, Petrosino JF, Mezzari MP, Okhuysen P, Eifel PJ, Jhingran A, Lin LL, Schmeler KM, Ramondetta L, Ajami N, Jenq RR, Futreal A, Zhang J, Klopp AH, Colbert LE. https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=1792&context=uthgsbs_docs. biology open 22(1):945, 2022. e-Pub 2022.
- Sims T, Floyd J, Sood A, Westin S, Fellman B, Unke J, Rangel K, Hilton T, Fleming N. Correlation of BRCA and HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer in the age of PARPi maintenance therapy (187). ScienceDirect 166:S107-S108, 2022. e-Pub 2022.
- Foster K, Handley K, Bhosale P, Glassman D, Sims T, Javadi S, Palmquist S, Saleh M, Fellman B, Fleming N, Sood A. Reading the signs: Radiographic characterization of morphologic subtypes of high-grade serous ovarian cancer (141) 166:S87-S88, 2022. e-Pub 2022.
- Colbert LE, Karpinets T, El Alam MB, Lynn EJ, Sammouri J, Lo D, Elnaggar JH, Wang R, Harris TA, Yoshida-Court K, Tomasic K, Bronk JK, Yanamandra AV, Olvera AV, Carlin LG, Sims T, Delgado Medrano AY, Solley T, Eifel PJ, Jhingran A, Joyner M, Lin L, Ramondetta LM, Futreal AM, Schmeler KM, Mathew G, Dorta-Estremera S, Zhang J, Wu X, Ajami NJ, Taniguchi C, Petrosino JF, Wargo J, Sastry K, Okhuysen PC, Klopp AH. https://www.medrxiv.org/content/10.1101/2022.04.26.22274346.abstract. medRxiv:2022.04. 26.22274346, 2022. e-Pub 2022.
- Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry K, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. AACR Meet Abstr Online 10(2):259-271, 2022. e-Pub 2022.
- Sims TT, Frumovitz M. Techniques in Gynecologic Oncology. Signature:75-86, 2022. e-Pub 2022.
- Sims TT, Escobar PF, Falcone T. Atlas of Robotic, Conventional, and Single-port Laparoscopy: A Practical Approach in Gynecology, 2022. e-Pub 2022.
- Sims TT, Jazaeri AA. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. UGC 31(11):1408-1409, 2021. e-Pub 2021.
- Sims T, Sood A, Westin S, Fellman B, Unke J, Rangel K, Hilton T, Fleming N. OP023/#658 Correlation of hrd status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline and maintenance therapy 31:A20-A21, 2021. e-Pub 2021.
- Bronk JK, Wu X, Chapman BV, Karpinets T, Sims T, Gjyshi O, Eifel PJ, Jhingran A, Lin LL, Ramondetta L, Futreal PA, Schmeler K, Yue J, Solley T, Ahmad-Kaddar M, Lynn EJ, Zhang J, Klopp AH, Colbert L. Dynamic Tumor Mutational Profiling Using a Novel Non-Invasive Swab Technique for Serial Whole Exome Sequencing of Cervical Tumors During Chemoradiation Therapy. astro, 2021. e-Pub 2021.
- Sims TT, Ramogola-Masire D, Ngoni K, et al. An analysis of tumor microbial diversity and composition between women with cervical cancer in Botswana and the United States. Gynecol Oncol, 2021. e-Pub 2021.
- Handley KF, Sims TT, Glassman D, Fleming ND, Lee S, Yao H, Yao J, Liu J, Bast RC, Westin SN, Celestino J, Rangel KM, Conrads TP, Maxwell GL, Ram PT, Sood AK. If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer. Oral Presentation, 2021. e-Pub 2021.
- Handley K, Sims T, Glassman D, Fleming N, Lee S, Fellman B, Yao H, Yao J, Liu J, Bast R, Lu Z, Westin S, Rangel K, Celestino J, Bateman N, Conrads T, Maxwell G, Ram P, Sood A. If looks could kill: morphologic subtypes of high-grade serous ovarian cancer. ScienceDriect 162:S20-S21, 2021. e-Pub 2021.
- Sims T, Ramogola-Masire D, Ngoni K, Biegert G, Solley T, Ning M, Alam ME, Mezzari M, Ramondetta L, Schmeler K, Colbert L, Jhingran A, Grover S, Klopp A. An analysis of tumor microbial diversity and composition between women with cervical cancer in Botswana and the United States. ScienceDirect 162:S87-S88, 2021. e-Pub 2021.
- Sims TT, Sood AK, Westin SN, Fellman B, Unke J, Rangel K, Hilton T, Fleming N. Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. Poster Presentation. 2021. American Society of Clinical Oncology (ASCO) Annual Meeting, 2021, 2021. e-Pub 2021.
- Colbert L, Alam ME, Lynn E, Edwards J, Karpinets T, Wu X, Chapman B, Sims T, Lin D, Kouzy R, Biegert G, Medrano AD, Olvera A, Sastry K, Eifel P, Jhingran A, Lin L, Ramondetta L, Futreal A, Jazaeri A, Schmeler K, Yue J, Mitra A, Wargo J, Solley T, Hegde V, Nookala S, Yanamandra A, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday E, Minsky B, Koong A, Koay E, Das P, Taniguchi C, Klopp A. Candidate HPV-Specific T-Cells Expand in the Tumor Microenvironment During Chemoradiotherapy. Research, 2021. e-Pub 2021.
- El Alam MB, Sims TT, Kouzy R, Biegert GW, Jaoude JA, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers 16(3):e0247905, 2021. e-Pub 2021.
- Biegert G, Alam MB, Karpinets T, Wu X, Sims TT. Yoshida-Court, 2021. e-Pub 2021.
- Sims TT, Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S. Yoshida-Court, K.; Wu, X.; Biegert, GWG; Delgado Medrano, AY; et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation 4:237, 2021. e-Pub 2021.
- Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude J, Karpinets TV. Yoshida-Court, K.; Wu, X.; Delgado-Medrano, AY; Mezzari, MP; et al. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers 16:e0247905. e-Pub 2021.
- Biegert G, Karpinets TV, Wu X, El Alam MB, Biegert G, Karpinets TV, Wu X, El Alam MB, Sims TT, Yoshida-Court K, Lynn E, Yue J, Medrano A, Petrosino J, Mezzari MP, Ajami NJ, Solly T, Ahmed-Kaddar M, Colbert LE, Klopp AH, Yoshida-Court K, Lynn E, Yue J, Medrano A, Petrosino J, Mezzari MP, Ajami NJ, Solly T, Ahmed-Kaddar M, Colbert LE, Klopp AH. Diversity and Composition of Gut Microbiome of Cervical Cancer Patients by 16S rRNA and Wholemetagenome Sequencing. Research Square, 2020. e-Pub 2020.
- Sims TT, Klopp AH. Intensified systemic therapy regimens in combination with definitive radiation for treatment of cervical cancer. ScienceDirect 30(4):265-272, 2020. e-Pub 2020.
- Biegert G, Karpinets T, Wu X, El Alam MB, Sims TT, Yoshida-Court K, Lynn EJ, Yue J, Medrano AD, Petrosino J, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Colbert LE, Klopp AH. Diversity and composition of gut microbiome of cervical cancer patients by 16S rRNA and whole-metagenome sequencing. bioRxiv, 2020. e-Pub 2020.
- El Alam MB, Sims TT, Kouzy R, Biegert GW, Jaoude JA, Karpinets TV, Yoshida-Court K, Wu X, Delgado Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. Adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. bioRxiv:2020.04. 10.036426, 2020. e-Pub 2020.
- Sims TT, El Alam MB, Karpinets TV, et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. medRxxiv online, 2020. e-Pub 2020.
- Sims TT, El Alarm MB, Karpinets T, etal. Gut microbiome diversity as an independent predictor of survival in cervical cancer patients receiving chemoradiation. J Clin Oncol, 2020. e-Pub 2020.
- Alam E, Sims TT, Kouzy R, et al. Adaptive changes in the gut microbiome during standard-of-care chemotherapy for gynecologic cancers. bioRxiv online, 2020. e-Pub 2020.
- Chapman BV, Karpinets T, Sims TT, Biegert G, Wu X, Medrano A, Eifel P, Jhingran A, Lin L, Ramondetta L, Futreal A, Jazaeri A, Frumovitz M, Schmeler K, Yue J, Mitra A, Court K, Solley T, Mathew G, Ahmed-Kaddar M, Zhang J, Klopp A, Colbert LE. Dynamic evolution of cervical cancer mutations during chemoradiation using novel sampling approach. BioRxiv preprint, 2019. e-Pub 2019.
- Sims, TT, Colbert LE, Zheng J, Hoffman KL, Ramondetta LM, Jazaeri AA, Frumovitz M, Jhingran A, Schmeler KM, Daniel-MacDougall CR, Klopp AH. Gut Microbial Diversity and Genus-level Differences Identified in Cervical Cancer Patients versus Age and BMI Matched Healthy Controls. Proceedings of the 2019 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; Gynecol Oncol, 2019. e-Pub 2019.
- Perkins V, Matsuo K, Mostofizadeh S, Sims TT, Lea JS, Carlson MJ, Roman LD, Monk BJ, Barnes DM, Chen S, Moore KN, Holman LL. Combining whole pelvic radiation with chemotherapy in stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol, 2017. e-Pub 2017.
- Liu C, Sims TT Kehoe S. Risk-Reducing Salpingo-Oophorectomy for BRCA carriers: is there a benefit to combined breast surgery?. Proceedings of the Annual Meeting of the American Congress of Obstetricians and Gynecologist, 2017. e-Pub 2017.
- Sims TT, Lavanya PP, Miller D, Lea JS, Carlson M. Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies. Proceedings of the 2017 Annual Meeting of the American Congress of Obstetricians and Gynecologist, 2017. e-Pub 2017.
- Perkins V, Carlson M, Sims TT, Lea JS, Chen S, Monk B, Moore K, Holman LL. The Potential Role of Pelvic Radiation in Stage IVB Cervical Carcinoma. Gynecol Oncol, 2016. e-Pub 2016.
- Sims TT, Fallen TJ, Dungan JS, Shulman LP. Testing for Familial BRCA1-2 Mutations: Implications for Genetic Counseling and Risk Assessment. Proceedings of the Sixty- Second Annual Meeting of the American Congress of Obstetricians and Gynecologist, 2014. e-Pub 2014.
Patient Reviews
CV information above last modified July 24, 2026